Expanding Brain PET Implementation
Catalyst MedTech has announced the continued national deployment of its Full Access Neurology solution, designed to support the implementation of Brain PET imaging programs across the United States. According to the company, the solution is intended to enable neurology practices, health systems, imaging providers, and clinical research sites to bring advanced imaging in-house.
As described by Catalyst MedTech, the focus is on enabling access to scalable, operational imaging solutions to support biomarker-driven diagnosis in Alzheimer’s disease and other neurodegenerative conditions.
From Technology to Operational Deployment
Catalyst MedTech states that while dedicated Brain PET systems are available, implementation remains a challenge. The Full Access Neurology solution is designed to address this by providing an end-to-end model for clinical deployment.
The platform integrates:
- Optimized, dedicated Brain PET technology powered by CareMiBrain
- Quantification and clinical workflow integration
- Nationwide service, support, and maintenance
- Flexible deployment models to enable rapid adoption
According to the company, this model is intended to allow providers to implement Brain PET imaging without the traditional barriers of capital, staffing, and infrastructure.
Building on Established Imaging Experience
Catalyst MedTech reports more than 26 years of experience implementing advanced imaging programs in nuclear cardiology. The company states that it is applying the same approach to neurology through the Full Access Neurology solution.
The solution combines imaging equipment, service, clinical integration, and operational support into a single model designed for scalability.
Supporting Brain PET Adoption
Recent developments, including the launch of dedicated Brain PET clinics in the U.S., reflect increasing demand for infrastructure to support biomarker-based diagnosis. These clinics are incorporating CareMiBrain technology as part of the Full Access Neurology solution.
The solution is designed to support:
- Earlier and more accurate diagnosis through biomarker-based imaging
- Improved patient access to advanced diagnostic tools
- Standardized imaging protocols for clinical care and research
- Scalable infrastructure to support growing demand for neuroimaging
Clinical Applications in Neurology
Catalyst MedTech states that Brain PET imaging can support diagnosis and clinical decision-making across multiple neurological conditions, including Alzheimer’s disease, Lewy body dementia, frontotemporal dementia, brain tumors, chronic traumatic encephalopathy (CTE), and psychiatric disorders.
“Today’s neurology care is to be defined by equitable access to advanced imaging for earlier diagnosis and more confident care decisions across Alzheimer’s disease and other neurologic conditions, including Lewy body dementia, frontotemporal dementia, brain tumors, chronic traumatic encephalopathy (CTE), and psychiatric disorders,” said Martin Shirley, President and CEO at Catalyst MedTech. “The availability of FDG, amyloid-targeting agents, and emerging tau-targeting agents amplifies the need to create access through advanced technology, proven clinical models, and new workflows from a single source.”
Implementation Focus
Catalyst MedTech states that the market focus is shifting toward how Brain PET can be implemented in clinical practice. Through its Full Access Neurology solution, the company aims to provide a model for integrating Brain PET imaging into routine workflows.
Source: Catalyst MedTech
